Local paclitaxel delivery after coronary stenting in an experimental animal model

Christoph Dommke; Karl K. Haase; Tim Süselbeck; Ines Streitner; Dariush Haghi; Jürgen Metz; Martin Borggrefe; Christian Herdeg

doi:10.1160/TH07-01-0074

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2007; 98(03): 674-680
DOI: 10.1160/TH07-01-0074

New Technologies, Diagnostic Tools and Drugs

Schattauer GmbH

Local paclitaxel delivery after coronary stenting in an experimental animal model

Christoph Dommke

¹Department of Cardiology, University of Mannheim, Mannheim, Germany

,

Karl K. Haase

²Department of Cardiology, Klinikum Reutlingen, Reutlingen, Germany

,

Tim Süselbeck

¹Department of Cardiology, University of Mannheim, Mannheim, Germany

,

Ines Streitner

¹Department of Cardiology, University of Mannheim, Mannheim, Germany

,

Dariush Haghi

¹Department of Cardiology, University of Mannheim, Mannheim, Germany

,

Jürgen Metz

³Department of Anatomy and Cell Biology, University of Heidelberg, Heidelberg, Germany

,

Martin Borggrefe

¹Department of Cardiology, University of Mannheim, Mannheim, Germany

,

Christian Herdeg

⁴Department of Cardiology, University of Tübingen, Tübingen, Germany

› Institutsangaben

Abstract

Summary

The goal of this study was to test the safety and efficacy of local paclitaxel delivery via a newly designed application catheter in an experimental animal study. Drug-eluting stents reduce restenosis in comparison to bare-metal stents. The drug-eluting polymer, however, may exert potential thrombogenic and inflammatory effects. A catheter-based local paclitaxel delivery offers further advantages, particularly a homogenous drug transfer into the vessel wall and a pharmacotherapy of the stent edges. In 30 pigs, both bare-metal stent (3.0 × 13mm) implantation and balloon angioplasty were performed. Ten pigs received subsequent local delivery of paclitaxel-solution via a newly designed catheter (Genie™, ACROSTAK corp., Switzerland), 10 animals served as a sham group and received vehicle (0.9% NaCl solution) and 10 animals were used as a control group. All animals were treated with aspirin and clopidogrel to prevent stent thrombosis. After final angiography the vessels were excised 42 days after intervention and prepared for histological and histomorphometric analysis. All coronary arteries showed complete endothelialization 42 days following treatment. Paclitaxel treatment led to a marked reduction of neointimal proliferation either post stent implantation (neointimal area: 1.04 ± 0.10 mm² vs. 2.37 ± 0.23 mm², p<0.001) or post balloon dilatation (neontimal area: 0.35 ± 0.14 mm², vs. 0.68 ± 0.24 mm², p<0.01).There were no significant angiographic or histomorphometric differences between the control and the sham group. In both paclitaxel groups neither angiographic edge phenomena nor a significant histomorphometric inflammatory response were found in the treated vessel segments. In conclusion, the local application of paclitaxel via the Genie™ catheter is safe and effective to significantly reduce the proliferative response post-stent implantation or balloon dilatation in an experimental animal model.

Keywords

Restenosis - angioplasty - paclitaxel - local drug delivery - Genie™

Volltext

Referenzen

References
1 Farb A, Sangiorgi G, Carter AJ. et al. Pathology of acute and chronic coronary stenting in humans. Circulation 1999; 99: 44-52.
2 Babapulle MN, Eisenberg MJ. Coated stents for the prevention of restenosis: Part I. Circulation 2002; 106: 2734-2740.
3 Babapulle MN, Eisenberg MJ. Coated stents for the prevention of restenosis: Part II. Circulation 2002; 106: 2859-2866.
4 Morice MC, Serruys PW, Sousa JE. et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-1780.
5 Stone GW, Ellis SG, Cox DA. et al. A polymerbased, paclitaxel- eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-231.
6 van der Giessen WJ, Lincoff AM, Schwartz RS. et.al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 1996; 94: 1690-1697.
7 Schrör K, Aron AW, Hohlfeld T. et al. Clopidogrel "resistance". Thromb Haemost 2004; 92: 229-231.
8 Grossmann R, Sokolova O, Schnurr A. et al. Variable extent of clopidogrel responsiveness in patients after coronary stenting. Thromb Haemost 2004; 92: 1201-1206.
9 Axel DI, Kunert W, Goggelmann C. et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997; 96: 636-645.
10 Schwartz RS, Huber KC, Murphy JG. et al. Restenosis and the proportional neointimal response to coronary artery injury: Results in a porcine model. J Am Coll Cardiol 1992; 19: 267-274.
11 Kornowski R, Hong MK, Tio FO. et al. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol 1998; 31: 224-230.
12 Keane D, Haase J, Slager CJ. et al. Comparative validation of quantitative coronary angiography systems. Results and implications from a multicenter study using a standardized approach. Circulation 1995; 91: 2174-2183.
13 Tanabe K, Serruys PW, Degertekin M. et al. Chronic arterial responses to polymer-controlled paclitaxel- eluting stents: comparison with bare metal stents by serial intravascular ultrasound analyses: data from the randomized TAXUS-II trial. Circulation 2004; 109: 196-200.
14 De Scheerder IK, Wilczek KL, Verbeken EV. et al. Biocompatibility of polymer-coated oversized metallic stents implanted in normal porcine coronary arteries. Atherosclerosis 1995; 114: 105-114.
15 Rechavia E, Litvack F, Fishbien MC. et al. Biocompatibility of polyurethane-coated stents: tissue and vascular aspects. Cathet Cardiovasc Diagn 1998; 45: 202-207.
16 Virmani R, Farb A, Guagliumi G. et al. Drug-eluting stents: caution and concerns for long-term outcome. Coron Artery Dis 2004; 15: 313-318.
17 Virmani R, Liistro F, Stankovic G. et al. Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation 2002; 106: 2649-2651.
18 Kotani J, Awata M, Nanto S. et al. Incomplete neointimal coverage of sirolimus- eluting stents: angiographic findings. J Am Coll Cardiol 2006; 47: 2108-2111.
19 Waksman R, Bhargava B, Mintz GS. et al. Late total occlusion after intracoronary brachytherapy for patients with in-stent restenosis. J Am Coll Cardiol 2000; 36: 65-68.
20 Cheneau E, Wolfram R, Leborqne L. et al. Understanding and preventing edge effects. J Interv Cardiol 2003; 16: 1-7.
21 Herdeg C, Oberhoff M, Baumbach A. et al. Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo. J Am Coll Cardiol 2000; 35: 1969-1976.
22 Creel CJ, Lovich MA, Edelman ER. Arterial paclitaxel distribution and deposition. Circ Res 2000; 86: 879-884.
23 Speck U, Scheller B, Abramjuk C. et al. Neointima inhibition: comparison of effectiveness of non- stentedbased local drug delivery and a drug eluting stent in porcine coronary arteries. Radiology 2006; 240: 411-418.
24 Schwartz RS, Edelmann ER, Carter A. et al. Drugeluting stents in per- clinical studies: recommended evaluation from a consensus group. Circulation 2002; 106: 1867-1873.
25 Scheller B, Speck U, Abramjuk C. et al. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation 2004; 110: 810-814.
26 Scheller B, Hehrlein C, Bocksch W. et al. Treatment of coronary in- stent restenosis with a paclitaxelcoated balloon catheter. N Engl J Med 2006; 355: 2113-2124.